Acute ischaemic coronary syndromes, the clinical sequelae of thrombosis over a fissured atherosclerotic plaque within the coronary circulation, are the leading cause of death and hospitalisation in Western countries. Platelets are fundamental for the initiation and continuation of thrombosis, and currently available anti-platelet agents such as aspirin significantly improve the clinical outcome of patients with these syndromes. Therapeutic success with available therapy is however not universal, and adverse clinical event rates remain high. Several new classes of agents with a variety of anti-platelet actions are currently under development. Those which inhibit the final common pathway of platelet aggregation, the glycoprotein (GP) IIb/IIIa receptor, appear to show the most promise. Much clinical trial evidence already exists supporting the use of GP IIb/IIIa receptor antagonists in the management of acute ischaemic coronary syndromes. Several clinical studies are underway to further refine this knowledge base, and to assess their efficacy in a variety of novel applications.

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.7.5.811DOI Listing

Publication Analysis

Top Keywords

acute ischaemic
12
ischaemic coronary
12
coronary syndromes
12
anti-platelet agents
8
management acute
8
syndromes clinical
8
iib/iiia receptor
8
clinical
5
ongoing clinical
4
clinical trials
4

Similar Publications

Late Endovascular Treatment for Ischemic Stroke with Moderate to Large Infarct Volume is Associated with a Better Clinical Prognosis.

Curr Neurovasc Res

January 2025

Center for Rehabilitation Medicine, Department of Neurology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.

Objective: The concept of "time is brain" is crucial for the reperfusion therapy of ischemic stroke. However, the Infarct Growth Rate (IGR) varies among individuals, which is regarded as a more powerful factor than the time when determining infarct volume and its association with clinical outcomes. For stroke patients with a similar infarct volume, a longer time from stroke Onset to Imaging (OTI) correlates with a lower IGR, which may indicate a better prognosis.

View Article and Find Full Text PDF

Background: Patients with acute myocardial infarction and angiographically obstructive non-culprit lesions are at high risk for recurrent major adverse cardiac events (MACEs). However, it remains largely unknown whether events are due to stenosis severity or due to the underlying high-risk lesion morphology.

Methods: Between January 2017 and December 2021, 1312 patients with acute myocardial infarction underwent optical coherence tomography of all the 3 main epicardial arteries after successful percutaneous coronary intervention.

View Article and Find Full Text PDF

Immune checkpoint inhibitors (ICIs), such as pembrolizumab, have revolutionized cancer therapy but can lead to severe immune-related adverse events (irAEs). We present a case of fulminant type 1 diabetes mellitus (T1DM) with diabetic ketoacidosis (DKA) and mesenteric ischemia in a 78-year-old woman with recurrent stage IIIC1 cervical cancer treated with pembrolizumab. Thirty-four days after initiating a pembrolizumab-containing regimen, she presented with vomiting, severe hyperglycemia, metabolic acidosis, and strongly positive urine ketones.

View Article and Find Full Text PDF

Introduction Whole-body computed tomography angiography (CTA) may be useful during cerebral angiography and endovascular treatment (EVT), and identification of thrombi and malignant trunk tumors may be helpful in stroke typing and acute stroke care. Therefore, we aimed to assess the types and prevalence of incidental findings on whole-body CTA in this patient population. Methods This single-center, retrospective, observational study included consecutive patients with suspected acute stroke who underwent whole-body CTA in addition to brain CTA between April 2020 and August 2023.

View Article and Find Full Text PDF

Myocardial bridging is a frequent anomaly of the heart in humans and other animals. A myocardial bridge is typically characterized by the systolic narrowing seen with traditional catheter angiography, but this abnormality is not by itself a sign of ischemia or the need for intervention. In particular, transient spontaneous angina must be corroborated by reproducible narrowing during acetylcholine testing; this narrowing occurs during resting conditions and is responsive to nitroglycerin administration.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!